Recent advances in cardiology.
During 2009, multiple major cardiology trials have been presented or published. In this paper, we summarize and place in clinical context the new trial findings regarding anticoagulation (dabigatran), antiplatelet therapy (ticagrelor, clopidogrel, prasugrel and aspirin), percutaneous coronary management (thrombectomy, multivessel/left main disease and biodegradable polymers), medical therapy for coronary disease (ivabradine and rosuvastatin) and management of heart failure (beta-blocker strategy, atrial fibrillation and resynchronization therapy).
Menown
Ian A
IA
Craigavon Cardiac Centre, Southern Trust, Northern Ireland, BT63 5QQ, UK. ian.menown@southerntrust.hscni.net
Shand
James A
JA
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D015906:Angioplasty, Balloon, Coronary / Q000639:trends; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial; D002309:Cardiology / Q000639:trends*; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000601:surgery / Q000628:therapy; D054855:Drug-Eluting Stents; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000188:drug therapy* / Q000601:surgery / Q000628:therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000925:Anticoagulants; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin